Tiny implanted 3-D printed scaffolds infused with antibiotics could revolutionise the way doctors prevent deadly ‘superbug’ infections post-surgery, saving lives and long hospital stays.
Genentech Inc. researchers have developed arylomycin derivatives with potent activity against Gram-negative bacteria, including multidrug resistant (MDR) strains. The small molecule could represent a notable step forward against Gram-negative bacteria, for which no new class of antibiotics has been approved in over 50 years.
Merck & Co., Inc. MRK announced that a late-stage study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections met the primary endpoints
Screen of human proteins reveals some with antimicrobial power
The Centers for Disease Control and Prevention is working with HP under a new pilot program involving BioPrinters. Four regional CDC labs are utilizing these HP BioPrinters to test new antibiotics at an accelerated rate, specifically focusing on drugs to fight against resistant bacteria. This is the first time regional labs will be able to rapidly test these new drugs.